CSL Limited (ASX:CSL – Get Free Report) insider Megan Clark bought 132 shares of the stock in a transaction on Wednesday, February 19th. The stock was purchased at an average price of A$264.85 ($167.63) per share, for a total transaction of A$34,959.94 ($22,126.54).
CSL Price Performance
The firm has a market capitalization of $77.43 billion, a price-to-earnings ratio of 28.02, a PEG ratio of 1.29 and a beta of 0.32. The company has a debt-to-equity ratio of 64.46, a current ratio of 1.86 and a quick ratio of 1.68.
CSL Increases Dividend
The firm also recently declared a Interim dividend, which will be paid on Tuesday, April 8th. Stockholders of record on Tuesday, April 8th will be given a $2.073 dividend. The ex-dividend date of this dividend is Sunday, March 9th. This represents a dividend yield of 0.81%. This is a positive change from CSL’s previous Interim dividend of $1.83. CSL’s payout ratio is 50.38%.
About CSL
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.
Featured Articles
- Five stocks we like better than CSL
- What is the S&P/TSX Index?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
- About the Markup Calculator
- Should You Hold NVIDIA Stock for the Long Haul or Trade It?
- Stock Average Calculator
- Humana Gains Despite Medicare Advantage Losses—What’s the Catch?
Receive News & Ratings for CSL Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CSL and related companies with MarketBeat.com's FREE daily email newsletter.
